5-Aminolevulinic Acid Fluorescence-Guided Resection of 18F-FET-PET Positive Tumor Beyond Gadolinium Enhancing Tumor Improves Survival in Glioblastoma

Michael Müther, Walter Stummer(University of Münster), Raphael Koch, Matthias Weckesser(University Hospital Münster), Peter B. Sporns(Triemli Hospital), Wolfram Schwindt(University Hospital Münster)

Neurosurgery

April 28, 2019

10.1093/neuros/nyz199

Cited by 46

Related Papers

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

|The Lancet Oncology|2006|3.4k

EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME

|Neurosurgery|2008|1k

Fluorescence-guided resection of glioblastoma multiforme utilizing 5-ALA-induced porphyrins: a prospective study in 52 consecutive patients

|Journal of neurosurgery|2000|880

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

|The Lancet|2019|581

What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?

|Neurosurgery|2015|368